DNMT3A is pivotal in epigenetic regulation through DNA methylation leading to chromatin silencing and its inhibitor azacitidine is used for patients with myelodysplastic syndrome and AML [8, 9]. This evidence concerns the gene DNMT3A and acute myeloid leukemia.